Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of May 20, 2025 in Sana Biotechnology, Inc. Lawsuit – SANA

Core Viewpoint - A class action securities lawsuit has been filed against Sana Biotechnology, Inc. alleging securities fraud that affected investors between March 17, 2023, and November 4, 2024 [1][2] Group 1: Allegations of Fraud - The lawsuit claims that Sana was at significant risk of having insufficient funds to maintain its operations and advance its product candidates [2] - It is alleged that product candidates SC291 in oncology, SC379, and SG299 were less promising than previously communicated to investors [2] - The company is likely to decrease funding for or discontinue certain product candidates and significantly reduce its headcount to preserve cash for more promising projects [2] - Defendants are accused of overstating Sana's financial capacity to maintain operations and advance existing product candidates [2] - Public statements made by the defendants were materially false and/or misleading throughout the relevant period [2] Group 2: Legal Process and Participation - Investors who suffered losses during the specified timeframe have until May 20, 2025, to request to be appointed as lead plaintiff [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees [3] Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has extensive expertise in complex securities litigation [4] - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the top securities litigation firms in the U.S. [4]